Modern drugs for obesity and metabolic syndrome treatment (Review)
The article reviews modern anti-obesity drugs to identify new trends in effective and safe risk factors reduction (diabetes, cardiovascular and musculoskeletal diseases, cancer). Some anti-obesity drugs have a high risk of adverse effects on the CNS and cardiovascular system, so they should be used...
Main Authors: | M. L. Maximov, O. V. Dralova, V. G. Kukes, V. N. Chubarev, V. V. Tarasov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
2022-12-01
|
Series: | Сеченовский вестник |
Subjects: | |
Online Access: | https://www.sechenovmedj.com/jour/article/view/575 |
Similar Items
-
A survey on clinical effectiveness of orlistat compared to sibutramine, lorcaserin, metformin and placebo on weight loss in obese people: a network meta-analysis
by: Somaye Fatahi, et al.
Published: (2018-09-01) -
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
by: Fernando Cordido, et al.
Published: (2010-01-01) -
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
by: Hurt RT, et al.
Published: (2018-09-01) -
Effect of sibutramine on cardiovascular events when administered in routine clinical practice
by: Nadezhda Sergeevna Dalantaeva
Published: (2015-12-01) -
The place of central-acting drugs in the algorithms of treatment of primary obesity
by: Oksana V. Logvinova, et al.
Published: (2017-09-01)